Form 4: Co-Diagnostics CEO Reports Stock Vesting and Tax Sale

Co-Diagnostics CEO Dwight H. Egan reported the vesting of restricted stock units and a mandatory 'sell to cover' transaction for tax obligations.

Summary

• Dwight H. Egan, Chief Executive Officer and Director of Co-Diagnostics, Inc. (CODX), reported changes in his beneficial ownership.
• On November 23, 2025, Egan acquired 163,333 shares of common stock upon the vesting of restricted stock units (RSUs).
• Concurrently, he disposed of 49,575 shares of common stock at a price of $0.35 per share.
• This disposition was a mandatory 'sell to cover' transaction to satisfy tax withholding obligations related to the RSU vesting, not a discretionary trade.
• Following these transactions, Egan's direct beneficial ownership of common stock is 748,252 shares.
• His beneficial ownership of derivative securities (Restricted Stock Units) is 412,500 units.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing is a routine disclosure of executive compensation vesting and a mandatory tax-related sale, which is not a discretionary action. The vesting itself is a positive for the executive and indicates ongoing incentive alignment, but the low sale price for tax purposes is a minor negative.

Positives

• The vesting of 163,333 restricted stock units indicates the ongoing execution of the company's long-term incentive plan for its CEO.
• The disposition of shares was explicitly stated as a non-discretionary 'sell to cover' transaction for tax purposes, suggesting no intent by the CEO to reduce personal exposure beyond what is legally required.

Negatives

• A disposition of 49,575 shares, even if for tax purposes, results in a reduction of the CEO's direct common stock holdings.
• The sale price of $0.35 per share for the tax-related disposition is relatively low.

Future Outlook

The filing details the ongoing vesting schedule for previously awarded restricted stock units, indicating a continued long-term incentive structure for the CEO through at least November 2025.

Management Comments

• The sale of 49,575 shares represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs.
• This sale is mandated by the Issuer's election, under its equity incentive plans, to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary trade by the Reporting Person.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, common across all publicly traded companies. It reflects standard equity compensation practices, where executives receive restricted stock units that vest over time, often accompanied by 'sell to cover' transactions for tax purposes. It does not provide specific industry-related insights beyond the company's internal compensation structure.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of executive compensation is a common practice in the biotechnology and diagnostics industry, aligning executive incentives with long-term shareholder value.
• The 'sell to cover' mechanism for tax withholding is a standard, non-discretionary method widely adopted by companies to manage tax obligations arising from equity awards, comparable to practices at companies like Abbott Laboratories or Thermo Fisher Scientific.
• The vesting schedule over multiple installments is typical for long-term incentive plans, similar to those seen in other mid-cap biotech firms.

Stakeholder Impact

• Shareholders: Provides transparency into executive stock ownership and compensation practices. The 'sell to cover' transaction is non-discretionary and minimal relative to total holdings, suggesting no negative signal regarding management's confidence.
• Employees: Reflects the company's ongoing use of equity-based compensation plans, which can be a positive for employee retention and motivation.

Next Steps

• Continued vesting of remaining restricted stock units according to the established schedules, with future installments commencing on dates such as May 23, 2023, November 23, 2023, November 23, 2024, and November 23, 2025.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation, specifically the vesting of restricted stock units and a mandatory 'sell to cover' transaction for tax purposes. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transactions are non-discretionary and part of a pre-established compensation plan, thus not signaling any change in management's confidence or outlook. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a compelling reason to buy or sell.

Keywords

Co-Diagnostics, CODX, Dwight H. Egan, Insider Trading, Form 4, Restricted Stock Units, RSU Vesting, CEO Stock, Equity Compensation, Sell to Cover